NVO

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: LLY AZN MRK PFE ABBV JNJ NVS BMY SNY AMGN

| Held by: AVDE PPH WCMI PID CNEQ IDVO APIE OZEM AVIV CORO

Scroll to Statements

Index	-
Market Cap	156.79B
Enterprise Value	171.34B
Income	18.19B
Sales	51.45B
Book/sh	7.66
Cash/sh	2.06
Dividend Est.	1.80 (3.84%)
Dividend TTM	1.80 (3.84%)
Dividend Ex-Date	Aug 17, 2026
Dividend Gr. 3/5Y	26.98% 19.93%
Payout	36.87%
Employees	68794
IPO	Apr 30, 1981

P/E	11.45
Forward P/E	14.09
PEG	-
P/S	3.05
P/B	6.12
P/C	22.79
P/FCF	13.29
EV/EBITDA	6.46
EV/Sales	3.33
Quick Ratio	0.66
Current Ratio	0.87
Debt/Eq	0.63
LT Debt/Eq	0.55
Option/Short	Yes / Yes

EPS (ttm)	4.09
EPS next Y	3.33
EPS next Q	0.77
EPS this Y	-7.93%
EPS next Y	-0.70%
EPS next 5Y	-0.42%
EPS past 3/5Y	26.28% 20.36%
Sales past 3/5Y	23.19% 19.21%
EPS Y/Y TTM	12.68%
Sales Y/Y TTM	13.21%
EPS Q/Q	-18.69%
Sales Q/Q	4.59%
Earnings	Aug 04 AMC
EPS/Sales Surpr.	23.99% 11.34%

Insider Own	0.00%
Insider Trans	-
Inst Own	9.83%
Inst Trans	-3.35%
ROA	21.81%
ROE	60.35%
ROIC	34.67%
Gross Margin	80.65%
Oper. Margin	45.38%
Profit Margin	35.36%
SMA20	-3.82%
SMA50	-0.19%
SMA200	0.36%
Trades

Shs Outstand	3.35B
Shs Float	3.35B
Short Float	0.93%
Short Ratio	2.45
Short Interest	31.09M
52W High	64.16 -26.96%
52W Low	35.12 33.43%
Volatility	4.51% 2.77%
ATR (14)	1.72
RSI (14)	46.23
Beta	0.76
Rel Volume	0.67
Avg Volume	12.70M
Volume	6,756,538

Perf Week	-0.47%
Perf Month	-4.13%
Perf Quarter	2.31%
Perf Half Y	8.12%
Perf YTD	-7.90%
Perf Year	-3.90%
Perf 3Y	-41.92%
Perf 5Y	-5.79%
Perf 10Y	87.93%
Recom	2.38
Target Price	49.10
Prev Close	45.97
Price	46.86
Change %	1.94%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-26-26	Initiated	Wolfe Research	Peer Perform
Mar-18-26	Initiated	Bernstein	Underperform
Mar-18-26	Initiated	Bernstein	Outperform	$175
Mar-10-26	Downgrade	TD Cowen	Buy → Hold	$42
Mar-03-26	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$40
Mar-02-26	Downgrade	Goldman	Buy → Neutral	$41
Feb-24-26	Downgrade	Kepler	Buy → Hold
Feb-24-26	Downgrade	JP Morgan	Overweight → Neutral
Feb-23-26	Downgrade	Deutsche Bank	Buy → Hold
Feb-12-26	Upgrade	Jefferies	Underperform → Hold
Jan-27-26	Initiated	Citigroup	Neutral
Dec-08-25	Downgrade	Argus	Buy → Hold
Oct-27-25	Resumed	Jefferies	Underperform
Oct-01-25	Upgrade	HSBC Securities	Hold → Buy
Sep-29-25	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$47
Sep-17-25	Upgrade	Berenberg	Hold → Buy
Sep-16-25	Upgrade	Rothschild & Co Redburn	Neutral → Buy
Sep-09-25	Upgrade	Bernstein	Mkt Perform → Outperform
Aug-13-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$54
Aug-05-25	Downgrade	UBS	Buy → Neutral

Show Previous Ratings

Today 12:34PM	Lilly and Novo Win a Key GLP-1 Antitrust Fight (GuruFocus.com)
06:41AM	The Week in Numbers: BP's huge profit, Toyota moves fast (Reuters Videos)
Aug-06-26 07:18PM	Lexicon Pharmaceuticals Inc (LXRX) (Q2 2026) Earnings Call Highlights: Zynquista NDA ... (GuruFocus.com)
01:19PM	Amazon Takes Bold Step Beyond Retail (GuruFocus.com)
01:04PM	Amazon Is Bringing the Weight-Loss Drug Race to Medicare (GuruFocus.com)
08:31AM	Loading…
08:31AM	Weight-loss drug Wegovy made Novo Nordisk Europes most valuable company. Finding its next blockbuster drug is proving difficult (Fortune)
07:30AM	33 stocks to bet on foreign markets continuing to beat the S&P 500 (MarketWatch)
07:18AM	Eli Lilly raises 2026 outlook again as Q2 soars past estimates (Pharmaceutical Technology)
Aug-05-26 03:46PM	Eli Lilly stock jumps as GLP-1 sales widen Novo lead (InvestorsHub)
02:30PM	Novo Nordisk Stock Falls 4% Despite Stronger GLP-1 Outlook (GuruFocus.com)
01:33PM	Stocks mixed with Nasdaq down; gold prices jump (Reuters)
12:52PM	How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy? (MarketWatch)
12:22PM	Novo Nordisk not currently in a position to pursue large-scale M&A, CEO says (Pharmaceutical Technology)
11:06AM	Novo Nordisk Swallows the Bitter Pill (Moby)
11:02AM	Eli Lilly is treating nearly 10% of US obesity population with GLP-1s: CFO (Yahoo Finance Video)
09:19AM	Loading…
09:19AM	Novo Nordisk looks to future proof as investors worry over pipeline (Reuters Videos)
08:01AM	Eli Lilly and Novo Nordisk raise profit outlook as demand for weight-loss drugs soars (Financial Times)
07:11AM	CVS shares jump on earnings beat, raised full-year guidance (Investing.com)
07:05AM	Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strong (Reuters)
07:04AM	Lilly's revenue soars 48%, driven by demand of its GLP-1s (MarketWatch)
06:50AM	Novo Nordisk shares fall despite improved outlook as Wegovy sales disappoint (InvestorsHub)
05:26AM	Middle East optimism lifts sentiment as SpaceX and AMD earnings dominate attention: Dow Jones, S&P, Nasdaq, Wall Street Futures (InvestorsHub)
05:18AM	European shares hover near record highs as earnings offset Mideast uncertainty (Reuters)
03:23AM	Novo Nordisk tumbles as Wegovy sales miss, trial setback overshadow raised outlook (Investing.com)
02:17AM	FTSE 100 Live: Next and Glencore provide results boost, SpaceX tumbles (Proactive)
Aug-04-26 04:01PM	The Wegovy pill's 'surprise miss' is one reason Novo Nordisk's stock is down (MarketWatch) -5.97%
04:00PM	NVO Stock Drops 6% Despite Raised Guidance As Investors Worry About Injectable GLP-1 Sales Future (Stocktwits)
02:20PM	Novo Nordisk Stock Drops on Wegovy Shortfall (The Wall Street Journal)
02:16PM	Novo Nordisk Raises Earnings Guidance. The Stock Sinks. (Barrons.com)
01:40PM	Novo Nordisk Q2 2026 earnings beat, raises full-year outlook (Quartz)
12:51PM	Loading…
12:51PM	Novo Nordisk: Q2 Earnings Snapshot (Associated Press)
12:00AM	Arrogance kills: Novo chief injects risk-taking into Ozempic maker (Financial Times)
Aug-03-26 11:02AM	Citi says Novo selloff overdone but GLP-1 worries keep it on the sidelines (Proactive)
10:55AM	Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison (IPO-Edge.com)
09:04AM	Earnings live updates: Snap stock surges as World Cup ads boost revenue, Whirlpool falls (Yahoo Finance)
Jul-31-26 08:52PM	NVO Stock Ends Three-Month Winning Streak As Novo Nordisks Key Heart Drug Flops, Competition Goes To Court (Stocktwits) -8.78%
05:56PM	BIOA, GLUE Stocks Clock Worst Day In Years Whats The NVO Connection? (Stocktwits)
04:50PM	Novo Nordisk stock sinks 9% as heart drug fails trial (InvestorsHub)
10:56AM	Novo Nordisk Stock Drops as Heart Drug Fails Late-Stage Trial (Barrons.com)
10:46AM	Novo Nordisk Suffers Another Pipeline Setback (GuruFocus.com)
10:44AM	Novo Nordisk Stock Falls 7% as ZEUS Trial Fails (GuruFocus.com)
09:54AM	Novo Nordisk's stock slumps after failed trial - adding to the company's woes (MarketWatch)
09:36AM	NVO Stock Slumps After Late-Stage Trial Fails Primary Goal Retail Says Current Revenue Drivers Still Intact (Stocktwits)
08:51AM	Novo Nordisk Stock Sinks on Disappointing Heart Drug Trial Results (Investopedia)
08:46AM	Novo Nordisk ziltivekimab heart drug fails phase 3 trial (Quartz)
08:35AM	Novo Nordisk Stock Drops After Drug Fails in Cardiovascular Trial (The Wall Street Journal)
08:31AM	Novo Nordisk Stock Tumbles on Late-Stage Trial Results (Schaeffer's Research)
08:05AM	Novo Nordisk stock tumbles 10% as key trial misses goal (Investing.com)
Jul-24-26 09:09AM	As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize (Barrons.com)
08:31AM	Novo Nordisk Seeks Injunction Against Eli Lilly Weight-Loss Ads (GuruFocus.com)
08:00AM	Novo Nordisk is asking a court to immediately block Eli Lilly's weight loss drug ads (Quartz)
07:56AM	Novo Nordisk seeks injunction to block Eli Lilly weight loss drug ads (Quartz)
06:50AM	Novo Nordisk Reportedly Escalates Legal Battle Against Eli Lilly Even As Analysts See LLY Leading The GLP-1 Race (Stocktwits)
06:38AM	Novo Nordisk seeks court order to halt Eli Lilly weight-loss drug advertisements (InvestorsHub)
Jul-23-26 01:13PM	Lilly Targets Early 2027 Filing for Next Obesity Drug (GuruFocus.com)
08:23AM	Eli Lilly Moves Closer To Another Weight-Loss Drug: Retatrutide Clears Two More Phase 3 Trials Ahead Of FDA Filing (Stocktwits)
Jul-22-26 12:01AM	Novo Nordisk Takes Rival Eli Lilly to Court Over Weight-Loss Ad Claims (The Daily Upside)
Jul-21-26 05:25PM	Novo accuses rival Eli Lilly of "deceptive" weight-loss drug ads (Axios)
02:56PM	Novo sues Lilly, claiming misleading ads in weight-loss drug battle (Reuters Videos)
12:37PM	The world is desperate for weight-loss drugs. But Big Pharma cant advertise them globally (CNN Business)
12:22PM	Novo sues Lilly after alleged misleading and false advertising campaign (Pharmaceutical Technology)
11:45AM	Pharma heavyweights clash over anti-obesity drug ads (AFP)
11:33AM	Novo Sues Lilly Over Weight-Loss Ad Claims (GuruFocus.com)
11:18AM	Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims (Proactive)
10:35AM	Novo Nordisk sues Eli Lilly, accusing it of false advertising (CBS News)
10:29AM	Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising (Barrons.com)
10:01AM	Weight-loss wars: Why Novo Nordisk is suing Eli Lilly (Yahoo Finance Video)
09:50AM	Novo Nordisk sues Eli Lilly over GLP-1 advertising claims in escalating legal battle (NVO, LLY) (InvestorsHub)
09:34AM	Popular Drug Maker Slams GLP-1 Peer on False Advertising (Schaeffer's Research)
08:51AM	Novo Nordisk Lawsuit Against Eli Lilly: Wegovy Maker Alleges Misleading Zepbound, Mounjaro Ads (Stocktwits)
08:19AM	Novo Nordisk sues Eli Lilly in high-stakes GLP-1 advertising feud (Investing.com)
08:18AM	Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications (MarketWatch)
08:05AM	Wegovy maker sues rival Eli Lilly over 'deliberately false' GLP-1 ads (USA TODAY)
07:52AM	Novo Nordisk sues Eli Lilly over misleading weight loss drug ads (Quartz)
07:50AM	Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads (Bloomberg)
07:36AM	Novo Nordisk accuses Eli Lilly of deceptive marketing in weight-loss fight (Financial Times)
Jul-20-26 09:22AM	Citi lifts Novo Nordisk target on strong GLP-1 pill launch (Proactive)
Jul-17-26 06:39AM	The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea (Yahoo Finance)
04:24AM	Compounders maintain a firm grip on the GLP-1 market (Pharma Voice)
Jul-16-26 11:28AM	Novo secures European approval for oral Wegovy to extend lead over Lilly (Pharmaceutical Technology)
Jul-15-26 04:04PM	Novo Nordisk Stock Rises After Wegovy Pill Captured 89% of U.S. Prescriptions (GuruFocus.com)
04:02PM	Lilly's Obesity Pill Trails Wegovy (GuruFocus.com)
01:49PM	NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill Retail Notes LLY Is Clearly Behind Its Danish Counterpart (Stocktwits)
11:04AM	UBS says market has turned too pessimistic on AI as themes climb back up rankings (Proactive)
Jul-14-26 08:00AM	Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill (BioPharma Dive)
07:34AM	Novo Nordisk signs pact to assess semaglutide implant (Just Food)
Jul-09-26 08:16AM	One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics (PR Newswire)
Jul-08-26 10:34AM	Novo Nordisk shares dip as latest prescription data points to GLP-1 pill slowdown (Proactive)
08:02AM	Leading bank backs European pharma as the cleaner alternative to the AI trade (Proactive)
07:11AM	Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant (Pharmaceutical Technology)
Jul-07-26 02:14PM	It can take as little as 5 minutes online to get prescribed a GLP-1 for weight loss. Why that's risky. (MarketWatch)
09:45AM	A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It (PR Newswire)
07:59AM	Kailera says obesity pill succeeds in late-stage trial in China (BioPharma Dive)
Jul-05-26 02:00AM	Trump's FDA May Soon Throw Its Weight Behind Peptides. Should You Buy In? (Barrons.com)
Jul-03-26 03:10PM	Hackers claim they stole Novo Nordisk's drug and AI secrets (Quartz)
11:53AM	Pfizer's monthly weight loss shot posted side effects similar to Wegovy in mid-stage trial (Quartz)
09:53AM	Microsoft Launches AI Adoption Firm (GuruFocus.com)
03:55AM	Microsoft launches Microsoft Frontier Company with $2.5bn investment (Verdict)
Jun-30-26 02:43PM	Millions of Americans can get Medicare to cover GLP-1s for weight loss starting this week. Here's how much it costs. (MarketWatch)
Jun-29-26 05:00AM	3 late-stage MASH drugs that could rival Rezdiffra (Pharma Voice)

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.

Executive VPMr. Karsten Munk Knudsen

PresidentMr. Maziar Mike Doustdar B.A.

EVP of R&DDr. Martin Holst Lange

EVP of PeopleMs. Tania Sabroe

Executive VP of Enterprise IT & Quality and Member of Management BoardMs. Thilde Hummel Bogebjerg

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Novo Nordisk ADR

Upgrade your Finviz experience